Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine (RECOVER)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00474058 |
|
Recruitment Status :
Completed
First Posted : May 16, 2007
Results First Posted : April 12, 2010
Last Update Posted : June 22, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Parkinson's Disease | Drug: Rotigotine Other: Placebo | Phase 3 |
The objective of this trial is to assess the effects of rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease. In addition, effects of rotigotine on specific nocturnal and non-motor symptoms of Parkinson´s disease will be evaluated.
After a Screening Period of up to 28 days subjects will be hospitalized for two nights. After the second overnight stay, subjects will be randomly assigned either to rotigotine patch or placebo patch. Afterwards patients will be titrated to their optimal dose. After subjects have reached their optimal dose (or the highest dose) they will be maintained on this dose for a certain period. At the end of maintenance the subjects will be hospitalized for two nights. Afterwards the doses will be continuously decreased.
Efficacy will be assessed by application of sleep quality scores, motor examination scores, and scores to evaluate non-motor symptoms of Parkinsons. Safety assessments include adverse events, 12-lead electrocardiograms, blood pressure and heart rate assessments, and laboratory checks.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 287 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Phase 3B, Multicenter, Multinational, Double-Blind, Placebo Controlled, 2-Arm Trial to Evaluate the Effect of the 24-Hour Transdermal Delivery of Rotigotine on the Control of Early Morning Motor Function, Sleep Quality, Nocturnal Symptoms, and Non-Motor Symptoms in Subjects With Idiopathic Parkinson's Disease |
| Study Start Date : | May 2007 |
| Actual Primary Completion Date : | March 2009 |
| Actual Study Completion Date : | March 2009 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Rotigotine
Rotigotine transdermal patch
|
Drug: Rotigotine
Rotigotine transdermal patches: 10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h) Optimal dosing: The maximum Rotigotine dose allowed is 16mg/24h Other Name: Neupro |
|
Placebo Comparator: Placebo
Placebo transdermal patch
|
Other: Placebo
Placebo transdermal patches |
- Change in Early Morning UPDRS Part III Score [ Time Frame: From baseline to end of maintenance (after 4 weeks maintenance) ]The Unified Parkinson´s Disease Rating Scale Part III score is an accepted and validated sumscore of 14 items for the assessment of motor function in Parkinson´s disease. Each of the 14 items in the UPDRS part III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities.
- Change in Parkinson's Disease Sleep Scale (PDSS) [ Time Frame: From baseline to end of maintenance (after 4 weeks maintenance) ]The Parkinson´s Disease Sleep Scale (PDSS) is a questionnaire with 15 questions to assess sleep and nocturnal disability in Parkinson´s disease. The item- scores can range between 0= never and 4= very often. The PDSS score is a sumscore of all 15 questions.
- Change in Nocturnal Akinesia, Dystonia, and Cramps Score (NADCS) [ Time Frame: From baseline to end of maintenance (after 4 weeks maintenance) ]Subjects were asked to assess nocturnal akinesia, dystonia and cramps, using an ordinal severity scale. While a score of 0= normal and 4= maximal severity, subjects could also rate their symptoms with values of 0.5, 1.5, 2.5, 3.5. The nocturnal akinesia score was used to evaluate motor performance while the dystonia and cramps scores were used to evaluate sleep.
- Change in Number of Nocturias [ Time Frame: From baseline to end of maintenance (after 4 weeks maintenance) ]Nocturia is the need to get up during the night and interrupt sleep in order to urinate. It is a typical nocturnal symptom of Parkinson´s disease. The change from baseline in number of nocturias was used to evaluate improvements in sleep disorders.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Early and advanced Idiopathic Parkinson Disease with early morning motor impairment
Exclusion Criteria:
- Atypical Parkinsonian syndromes
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00474058
| United States, California | |
| Reseda, California, United States | |
| Ventura, California, United States | |
| United States, Florida | |
| St. Petersburg, Florida, United States, 33701 | |
| United States, North Carolina | |
| Salisbury, North Carolina, United States, 28144 | |
| Winston_Salem, North Carolina, United States | |
| United States, Rhode Island | |
| Warwick, Rhode Island, United States | |
| United States, Texas | |
| Houston, Texas, United States | |
| Australia, New South Wales | |
| Concord, New South Wales, Australia | |
| Australia, South Australia | |
| Adelaide, South Australia, Australia | |
| Australia | |
| Fitzroy, Australia | |
| Austria | |
| Innsbruck, Austria, 6020 | |
| Finland | |
| Hyvinkää, Finland | |
| Oulu, Finland, 90220 | |
| Germany | |
| Berlin, Germany, 10713 | |
| Berlin, Germany, 12163 | |
| Dresden, Germany, 01307 | |
| Kassel, Germany, 34128 | |
| Leipzig, Germany | |
| Marburg, Germany, 35039 | |
| Naumburg, Germany | |
| Ulm, Germany, 89081 | |
| Hungary | |
| Budapest, Hungary | |
| Debrecen, Hungary | |
| Nyiregyhaza, Hungary | |
| Zalaegerszeg, Hungary | |
| Italy | |
| Chieti, Italy, 66013 | |
| Milano, Italy | |
| Torino, Italy | |
| New Zealand | |
| Christ Church, New Zealand | |
| Wellington, New Zealand | |
| Poland | |
| Gdansk, Poland | |
| Krakow, Poland | |
| Lublin, Poland | |
| Olsztyn, Poland | |
| Szczecin, Poland | |
| Warszawa, Poland | |
| South Africa | |
| Cape Town, South Africa | |
| Capetown, South Africa | |
| Johannesburg, South Africa | |
| Pretoria/Gauteng, South Africa | |
| Tygerberg, South Africa | |
| Spain | |
| Barcelona, Spain, 08036 | |
| Madrid, Spain | |
| United Kingdom | |
| Bristol, United Kingdom | |
| Lancashire, United Kingdom | |
| Liverpool, United Kingdom | |
| London, United Kingdom | |
| Study Director: | UCB Clinical Trial Call Center | +1 877 822 9493 (UCB) |
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | UCB Pharma |
| ClinicalTrials.gov Identifier: | NCT00474058 |
| Other Study ID Numbers: |
SP0889 EudraCT No.: 2006-006752-35 ( Other Identifier: EudraCT ) |
| First Posted: | May 16, 2007 Key Record Dates |
| Results First Posted: | April 12, 2010 |
| Last Update Posted: | June 22, 2015 |
| Last Verified: | May 2015 |
|
rotigotine Neupro® Parkinson's Disease |
|
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders Synucleinopathies |
Neurodegenerative Diseases Rotigotine Dopamine Agonists Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |